Zyla Life Sciences Revenue Growth Rates (EGLT), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Zyla Life Sciences  (EGLT)
 

EGLT's Revenue Growth by Quarter and Year

Zyla Life Sciences's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

EGLT Revenue (in millions $) FY 2020 FY 2019 FY 2018 FY 2017
4th Quarter December -
3rd Quarter September -
2nd Quarter June -
1st Quarter March 19.07
FY 19.07

EGLTs Annual Revenue
Zyla Life Sciences's Revenue in the fiscal year 2019 $ 30.35 millions
Zyla Life Sciences's Revenue in the fiscal year 2018 $ 30.35 millions
Zyla Life Sciences's Revenue in the fiscal year 2017 $ 26.14 millions
Zyla Life Sciences's Revenue in the fiscal year 2016 $ 16.96 millions
Zyla Life Sciences's Revenue in the fiscal year 2015 $ 22.83 millions




EGLT Revenue first quarter 2020 Y/Y Growth Comment
Zyla Life Sciences reported Revenue surge of 204.57% year on year in the first quarter 2020, to $ 19.07 millions, this is lower than Zyla Life Sciences's recent average Revenue surge of 221.7%.

Looking into first quarter 2020 results within Major Pharmaceutical Preparations industry 22 other companies have achieved higher Revenue growth. While Zyla Life Sciences' s Revenue doubling of 204.57% ranks overall at the positon no. 128 in the first quarter 2020.


EGLT Revenue ( Y/Y Growth %) 2020
 2019 2018 2017
4th Quarter December - - 8.97 % 27.04 %
3rd Quarter September - 174.72 % 22.56 % 41.19 %
2nd Quarter June - 196.1 % 18.85 % 81.45 %
1st Quarter March 204.57 % 0 % 15.29 % 104.14 %
FY   - 0 % 16.11 % -

Financial Statements
Zyla Life Sciences's first quarter 2020 Revenue $ 19.07 millions EGLT's Income Statement
Zyla Life Sciences's first quarter 2019 Revenue $ 6.26 millions Quarterly EGLT's Income Statement


EGLT Revenue (Quarter on Quarter Growth %)

 2020
 2019 2018 2017
4th Quarter December - - 4.29 % 17.29 %
3rd Quarter September - 1.63 % 9.54 % 6.23 %
2nd Quarter June - 251.92 % 18.85 % 15.29 %
1st Quarter March - -26.35 % -19.74 % -11.56 %
FY (Year on Year)   - 0 % 16.11 % -


Back to EGLT Growth rate Comparisons >> Back to EGLT Growth rate Comparisons >>


Revenue first quarter 2020 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #23
Healthcare Sector #40
Overall #128

Revenue Y/Y Growth Statistics
High Average Low
2240.58 % 221.7 % -68.32 %
(Dec 31 2015)  
Revenue first quarter 2020 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #23
Healthcare Sector #40
Overall #128
Revenue Y/Y Growth Statistics
High Average Low
2240.58 % 221.7 % -68.32 %
(Dec 31 2015)  

Revenue by Quarter for the Fiscal Years 2017, 2018, 2019, 2020

Zyla Life Sciences's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


EGLT's I. Quarter Q/Q Revenue Comment
Improvement I. Quarter 2020where Zyla Life Sciences published Revenue of $ 19.07 millions should is starting point of positive performance.Zyla Life Sciences announced in the I. Quarter 2020 Revenue of $ 19.07 millions compare to recorded in previos quarter.

Within Major Pharmaceutical Preparations industry Zyla Life Sciences achieved highest sequential Revenue growth. While Zyla Life Sciences's Revenue growth quarter on quarter, overall rank is .


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


EGLT's I. Quarter Q/Q Revenue Comment
Improvement I. Quarter 2020where Zyla Life Sciences published Revenue of $ 19.07 millions should is starting point of positive performance.Zyla Life Sciences announced in the I. Quarter 2020 Revenue of $ 19.07 millions compare to recorded in previos quarter.

Within Major Pharmaceutical Preparations industry Zyla Life Sciences achieved highest sequential Revenue growth. While Zyla Life Sciences's Revenue growth quarter on quarter, overall rank is .


Zyla Life Sciences's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2020)		 12 Months Ending
(Dec 31 2019)		 12 Months Ending
(Sep 30 2019)		 12 Months Ending
(Jun 30 2019)		 12 Months Ending
(Mar 31 2019)
Cumulative Revenue 12 Months Ending $ 43.16 $ 30.35 $ 59.18 $ 44.94 $ 30.35
Y / Y Revenue Growth (TTM) 42.19 % 0 % 99.52 % 59.61 % 12.54 %
Year on Year Revenue Growth Overall Ranking # 989 # 2121 # 159 # 317 # 1155
Seqeuential Revenue Change (TTM) 42.19 % -48.71 % 31.67 % 48.07 % 0 %
Seq. Revenue Growth (TTM) Overall Ranking # 407 # 3349 # 146 # 98 # 2003


Cumulative Revenue growth Comment
Although Zyla Life Sciences's Annual Revenue growth year on year were below company's average 197.22% , Revenue announced in the Mar 31 2020 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 42.19% year on year, from 0% in Dec 31 2019.

In the Healthcare sector 190 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 989, from total ranking in previous quarter at 2121.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 51
Healthcare Sector # 191
Overall # 989

Revenue TTM Y/Y Growth Statistics
High Average Low
1089.06 %
 197.22 %
-25.69 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 51
Sector # 106
S&P 500 # 407
Cumulative Revenue growth Comment
Although Zyla Life Sciences's Annual Revenue growth year on year were below company's average 197.22% , Revenue announced in the Mar 31 2020 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 42.19% year on year, from 0% in Dec 31 2019.

In the Healthcare sector 190 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 989, from total ranking in previous quarter at 2121.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 51
Healthcare Sector # 191
Overall # 989

Revenue TTM Y/Y Growth Statistics
High Average Low
1089.06 %
197.22 %
-25.69 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 51
Sector # 106
S&P 500 # 407




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
EGLT's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue doubling for the quarter ending Mar 31 2020 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2020
Orgenesis Inc 348.21%$ 348.210 millions
Rigel Pharmaceuticals Inc341.71%$ 341.706 millions
Immunitybio inc 320.00%$ 320.000 millions
Option Care Health Inc 294.20%$ 294.197 millions
Old Ayala Inc 277.74%$ 277.736 millions
Ainos Inc 272.91%$ 272.915 millions
Eyepoint Inc 272.22%$ 272.217 millions
Theravance Biopharma inc 272.09%$ 272.087 millions
Elite Pharmaceuticals Inc 268.01%$ 268.010 millions
American Cryostem Corporation264.03%$ 264.034 millions
Chinook Therapeutics Inc 254.24%$ 254.241 millions
Voyager Therapeutics Inc 247.64%$ 247.643 millions
Aytu Biopharma Inc243.01%$ 243.015 millions
Telesis Bio Inc 215.74%$ 215.739 millions
Coherus Oncology inc 213.17%$ 213.171 millions
Therapeuticsmd Inc 210.41%$ 210.406 millions
Bioadaptives Inc 210.33%$ 210.333 millions
Harpoon Therapeutics Inc 210.16%$ 210.160 millions
Gw Pharmaceuticals Plc207.37%$ 207.369 millions
Zyla Life Sciences204.52%$ 204.520 millions
Verastem Inc 202.57%$ 202.573 millions
Alnylam Pharmaceuticals Inc 198.78%$ 198.781 millions
Adma Biologics Inc 189.06%$ 189.060 millions
Outset Medical Inc 188.64%$ 188.639 millions
Agios Pharmaceuticals Inc 188.15%$ 188.146 millions
Healthlynked Corp187.52%$ 187.520 millions
Editas Medicine Inc 176.61%$ 176.607 millions
Checkpoint Therapeutics inc 176.14%$ 176.136 millions
Albireo Pharma inc 171.75%$ 171.754 millions
Surface Oncology Inc 167.37%$ 167.369 millions


About Zyla Life Sciences Revenue Growth Rates (EGLT), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: the company’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.